MINNEAPOLIS—DaVita Clinical Research has started to offer Biorepository Services, which offer the pharmaceutical industry collaborative research opportunities that combine access to samples combined with patient data annotation.
“We are excited to begin this new chapter and believe the biorepository we are creating will set a new standard in the industry and add value to the drug discovery efforts of our partners,” stated DCR President Chris Rucker. “We believe that the unique characteristics of our offering will position us to meet a need in the discovery community that is currently not being satisfied by the existing biorepositories.”
The DCR biorepository provides customized sample sets from patient populations collected nationally. These samples are collected under an IRB-approved protocol with the consent of patients. The samples contain high RNA and DNA yields and are suitable for genomic analysis. In addition, DCR collects samples under the same rigorous conditions that allow proteomic and metabolomic testing.
Biorepository Services support industry trends toward personalized medicine, empowered drug discovery and productive drug development for biotechnology and pharmaceutical sponsors, as well as platform technology companies, according to DCR.
“Our unprecedented levels of operational excellence ensure that our partners not only have a sample for testing of the highest level of sample integrity, but the well-characterized data associated with it, including patient health history, treatment data, prescription data and hospitalization data,” said Mahesh Krishnan, MD, DCR vice president of clinical research. “It is the characterization of our data and the annotation of this data to our sample sets that distinguish our biorepository services from the majority of the industry.”
